ADMA - ADMA Biologics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Ramsey,
United States
Type: Equity
ADMA price evolution
ADMA
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $88.24 | $45.33 | $51.35 | |
| Short term investments | ||||
| Net receivables | $50.14 | $30.11 | $49.62 | $27.42 |
| Inventory | $171.8 | $179.81 | $177.73 | $172.91 |
| Total current assets | $318.19 | $303.69 | $276.42 | $257.01 |
| Long term investments | ||||
| Property, plant & equipment | $62.59 | $63.48 | $64.71 | $63.47 |
| Goodwill & intangible assets | $4.01 | $3.85 | $4.03 | |
| Total noncurrent assets | $72.71 | $74.46 | $72.17 | |
| Total investments | ||||
| Total assets | $390.62 | $376.4 | $350.88 | $329.18 |
| Current liabilities | ||||
| Accounts payable | $16.02 | $14.18 | $17.19 | $15.66 |
| Deferred revenue | $2.75 | $2.77 | $1.87 | |
| Short long term debt | $1.14 | $1.09 | $1.04 | |
| Total current liabilities | $44.89 | $44.18 | $53.09 | $49.81 |
| Long term debt | $101.33 | $131.07 | $130.85 | $130.59 |
| Total noncurrent liabilities | $143.95 | $144.08 | $144.17 | |
| Total debt | $132.22 | $131.94 | $131.64 | |
| Total liabilities | $158.73 | $188.13 | $197.17 | $193.98 |
| Shareholders' equity | ||||
| Retained earnings | -$420.48 | -$456.39 | -$488.45 | -$506.26 |
| Other shareholder equity | ||||
| Total shareholder equity | $188.27 | $153.71 | $135.21 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $51.35 | $86.52 | $51.09 | $55.92 |
| Short term investments | ||||
| Net receivables | $27.42 | $15.51 | $28.58 | $13.24 |
| Inventory | $172.91 | $163.28 | $124.72 | $81.54 |
| Total current assets | $257.01 | $270.4 | $208.73 | $153.74 |
| Long term investments | ||||
| Property, plant & equipment | $63.47 | $68.75 | $58.2 | $45.85 |
| Goodwill & intangible assets | $4.03 | $4.54 | $5.26 | $5.97 |
| Total noncurrent assets | $72.17 | $78.06 | $67.52 | $53.93 |
| Total investments | ||||
| Total assets | $329.18 | $348.46 | $276.25 | $207.67 |
| Current liabilities | ||||
| Accounts payable | $15.66 | $13.23 | $12.43 | $11.07 |
| Deferred revenue | $1.87 | $1.98 | $2.12 | $2.26 |
| Short long term debt | $1.04 | $0.91 | $0.59 | $0.37 |
| Total current liabilities | $49.81 | $39.27 | $30.38 | $19.95 |
| Long term debt | $130.59 | $142.83 | $94.87 | $92.97 |
| Total noncurrent liabilities | $144.17 | $157.22 | $104.7 | $99.48 |
| Total debt | $131.64 | $143.74 | $95.46 | $93.33 |
| Total liabilities | $193.98 | $196.49 | $135.08 | $119.42 |
| Shareholders' equity | ||||
| Retained earnings | -$506.26 | -$478.02 | -$412.11 | -$340.47 |
| Other shareholder equity | ||||
| Total shareholder equity | $135.21 | $151.97 | $141.17 | $88.25 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $107.19 | $81.88 | $73.9 | |
| Cost of revenue | $49.74 | $42.77 | $42.82 | |
| Gross Profit | $57.45 | $39.11 | $31.09 | |
| Operating activities | ||||
| Research & development | $0.56 | $0.45 | $0.45 | |
| Selling, general & administrative | $16.61 | $15.64 | $15.53 | |
| Total operating expenses | $18.25 | $17.29 | $16.85 | |
| Operating income | $39.2 | $21.82 | $14.23 | |
| Income from continuing operations | ||||
| EBIT | $39.63 | $22.17 | -$11.43 | |
| Income tax expense | $3.79 | $0.59 | ||
| Interest expense | $3.78 | $3.77 | $6.21 | |
| Net income | ||||
| Net income | $32.06 | $17.81 | -$17.64 | |
| Income (for common shares) | $32.06 | $17.81 | -$17.64 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $258.21 | $154.08 | $80.94 | $42.22 |
| Cost of revenue | $169.27 | $118.81 | $79.77 | $61.29 |
| Gross Profit | $88.94 | $35.27 | $1.17 | -$19.07 |
| Operating activities | ||||
| Research & development | $3.3 | $3.61 | $3.65 | $5.91 |
| Selling, general & administrative | $59.02 | $52.46 | $42.9 | $35.05 |
| Total operating expenses | $67.31 | $74.63 | $59.55 | $45.84 |
| Operating income | $21.63 | -$39.37 | -$58.37 | -$64.91 |
| Income from continuing operations | ||||
| EBIT | -$3.21 | -$46.62 | -$58.59 | -$63.76 |
| Income tax expense | ||||
| Interest expense | $25.03 | $19.28 | $13.06 | $11.99 |
| Net income | ||||
| Net income | -$28.24 | -$65.9 | -$71.65 | -$75.75 |
| Income (for common shares) | -$28.24 | -$65.9 | -$71.65 | -$75.75 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | $32.06 | $17.81 | -$17.64 | |
| Operating activities | ||||
| Depreciation | $2.05 | $2.11 | $2.11 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $2.86 | $2.14 | $1.75 | |
| Total cash flows from operations | $45.65 | -$2.22 | $17.6 | |
| Investing activities | ||||
| Capital expenditures | -$2.07 | -$2.35 | -$1.2 | |
| Investments | ||||
| Total cash flows from investing | -$5.83 | -$2.37 | -$2.36 | -$1.41 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.33 | $1.03 | $0.01 | |
| Net borrowings | -$25.17 | |||
| Total cash flows from financing | -$27.28 | -$0.36 | -$1.45 | -$38.99 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $35.36 | $42.92 | -$6.03 | -$22.81 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$28.24 | -$65.9 | -$71.65 | -$75.75 |
| Operating activities | ||||
| Depreciation | $8.33 | $7.11 | $5.5 | $3.94 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $6.19 | $5.21 | $3.49 | $2.86 |
| Total cash flows from operations | $8.8 | -$59.51 | -$112.37 | -$102 |
| Investing activities | ||||
| Capital expenditures | -$4.77 | -$13.91 | -$13.51 | -$12.72 |
| Investments | ||||
| Total cash flows from investing | -$4.98 | -$13.91 | -$13.51 | -$12.72 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $1.1 | $64.82 | $121.14 | $131.21 |
| Net borrowings | -$25.19 | $51.71 | -$0.03 | $13.52 |
| Total cash flows from financing | -$38.99 | $108.85 | $121.05 | $143.9 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$35.17 | $35.43 | -$4.83 | $29.17 |
News
Fundamentals
| Market cap | $4.39B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 236.38M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 1.43 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 7.09 |
| Quick ratio | 3.26 |